Zhengye Biotechnology Holding Limited (ZYBT)
NCM · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About Zhengye Biotechnology Holding Limited
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 260.3M | 211.7M | 186.4M | 116.4M |
| Gross Profit | 147.9M | 117.5M | 91.3M | 23.9M |
| Operating Income | 66.1M | 47.6M | 17.2M | -68.3M |
| Net Income | 46.7M | 31.5M | 11.3M | -69.8M |
| Diluted EPS | $0.99 | $0.67 | $0.24 | $nan |